Global Covid vaccine rollout threatened by shortage of vital components

Pharmaceutical firms warn of delays to items such as the large bags in which vaccine cells are grown

Vaccine-makers around the world face shortages of vital components including large plastic growbags, according to the head of the firm that is manufacturing a quarter of the UK’s jab supply.

Stan Erck, the chief executive of Novavax – which makes the second vaccine to be grown and bottled entirely in Britain – told the Observer that the shortage of 2,000-litre bags in which the vaccine cells were grown was a significant hurdle for global supply.

His warning came as bag manufacturers revealed that some pharmaceutical firms were waiting up to 12 months for the sterile single-use disposable plastic containers, which are used to make medicines of all kinds, including the Pfizer, Moderna and Novavax Covid-19 vaccines.

But Erck and his British partners said they were confident they had enough suppliers to avoid disruption to the supply of Novavax. The vaccine is waiting for approval from the Medicines and Healthcare products Regulatory Agency (MHRA) but the first of 60 million doses ordered by the government are already in production in Teesside.

The Fujifilm Diosynth Biotechnologies factory began growing the first cells for the Novavax vaccine in Billingham, County Durham this month and in a few weeks they will fill the bioreactor bag, ready to be transported to GlaxoSmithKline’s plant at Barnard Castle to be put into vials for distribution.

“The first hurdle is showing it works and we don’t have that hurdle any more,” Erck said.

But he added there were others still to overcome. “There’s the media that the cells have to grow in,” Erck said. “You grow them in these 2,000-litre bags, which are in short supply. Then you pour it out and you have to filter it, and the filters are in short supply. The little things count.”

Novavax almost ran out of bags at one of its 20 factories earlier this year, but there had been no delays for the UK operation, according to Martin Meeson, global chief executive of Fujifilm Diosynth.

“We started working on our part of the supply chain in summer last year,” he said. “We had to accelerate some of the investment here, but the commitment we made last summer to start manufacturing in February has been fulfilled.”

Production of coronavirus vaccines is being ramped up.
Production of coronavirus vaccines is being ramped up. Photograph: Christophe Archambault/AP

Both Meeson and Erck said the UK’s vaccine taskforce had been helpful in sorting out supply issues so far, but other countries and other medical supplies might be affected.

ABEC makes bioreactor bags at two plants in the US and two in Fermoy and Kells in Ireland, and delivered six 4,000-litre bags to the Serum Institute in India last year for its Covid vaccines.

Brady Cole, vice-president of equipment solutions at ABEC, said: “We are hearing from our customer base of lead times that are pushing out to nine, 10, even 12 months to get bioreactor bags. We typically run out at 16 weeks to get a custom bioreactor bag out to a customer.” He said ABEC was still managing to fulfil orders at roughly that rate.

“The bag manufacturing capacity can’t meet demand right now,” he added. “And on the component side, the tubes and the instruments and so forth that also go into the bag assembly – those lead times are also starting to get stretched as well. But the biggest problem we see is it really is just the ability to get bags in a reasonable amount of time.”

ABEC expanded its factories last year and has now started making 6,000-litre bags, which are roughly the size of a minibus. Other firms including MilliporeSigma, part of German company Merck, have also been expanding their manufacturing facilities. American firm Thermo Fisher Scientific expects it will finish doubling its capacity this year.

The US government has also blocked exports of bags, filters and other components so it can supply more Pfizer vaccines for Americans. Adar Poonawalla, the chief executive of the Serum Institute of India, said the restrictions were likely to cause serious bottlenecks.

Novavax is hoping to avoid delays and “vaccine nationalism” by operating on four continents, with 20 facilities in nine countries.

“One year ago, we had exactly zero manufacturing capacity,” Erck said. “We’re self-sufficient. The two main things we need to do are done in the UK. And in the EU we have plants in Spain and the Czech Republic and fill-and-finish in Germany and the Netherlands.”

There was no need for vaccines to cross borders to fulfil contracts, he said.

The Oxford/AstraZeneca vaccine was hit by a delay to a delivery of 5 million doses from India and a problem with a batch made in Britain, and the company has been dragged into a lengthy row between the UK and the EU over vaccine exports.

Contributor

James Tapper

The GuardianTramp

Related Content

Article image
I’ve had my first vaccine jab. It gives me hope of liberation... but not yet
Exactly a year after his first story about coronavirus, our science editor received the Pfizer injection last week. Here he reflects on a remarkable scientific achievement

Robin McKie Science Editor

24, Jan, 2021 @7:00 AM

Article image
Vaccine experts defend UK decision to delay second Pfizer Covid jab
Medics told they risk undermining public confidence by querying policy of three-month gap between doses

Michael Savage, Robin McKie and James Tapper

23, Jan, 2021 @10:30 PM

Article image
Pfizer and AstraZeneca ‘highly effective’ against India Covid variant
A Public Health England study has revealed the vaccines can be up to 88% effective after a second dose

Robin McKie

22, May, 2021 @6:28 PM

Article image
'The more vaccine projects we have, the better our chances'
Leading scientist warns of stumbles along the way to Covid-19 immunisation

Robin McKie

28, Mar, 2020 @8:06 PM

Article image
UK scientists look at reducing boosters to save vaccine for rest of the world
JCVI considers lower third jab dosage to release stocks for poorer nations

Michael Savage

22, Aug, 2021 @9:56 AM

Article image
New Covid variants ‘would set us back a year’, experts warn UK government
Vaccine-beating variant is ‘realistic possibility’, say scientists, amid calls for contingency plans to be revealed

Michael Savage

14, Aug, 2021 @11:01 PM

Article image
Two new vaccines on the way – with more to follow this year
Half of UK adults have had a first jab, and future supplies of millions of doses look assured

Robin McKie

04, Apr, 2021 @6:00 AM

Article image
UK might not be over the worst, scientists warn, as Covid case numbers stay high
Inoculation programme must be stepped up before the onset of winter

Robin McKie

03, Oct, 2021 @6:45 AM

Article image
UK doing more than most to help poor get Covid vaccine, study finds
Campaign scoring countries for global access efforts calls for more British transparency

Sarah Boseley Health editor

30, Sep, 2020 @2:00 PM

Article image
Under-30s reluctant to take Covid vaccine cite fertility and side-effect concerns
Fears over ‘experimental’ inoculation show that more needs to be done to counter harmful misinformation

James Tapper & Alex Mistlin

24, Jul, 2021 @5:38 PM